stoxline Quote Chart Rank Option Currency Glossary
  
Corvus Pharmaceuticals, Inc. (CRVS)
1.82  0.03 (1.68%)    03-28 12:20
Open: 1.79
High: 1.85
Volume: 184,353
  
Pre. Close: 1.79
Low: 1.762
Market Cap: 89(M)
Technical analysis
2024-03-28 11:46:38 AM
Short term     
Mid term     
Targets 6-month :  2.53 1-year :  2.86
Resists First :  2.17 Second :  2.45
Pivot price 1.89
Supports First :  1.72 Second :  1.43
MAs MA(5) :  1.78 MA(20) :  1.96
MA(100) :  1.88 MA(250) :  1.92
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  11 D(3) :  9
RSI RSI(14): 37.7
52-week High :  4.19 Low :  0.72
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CRVS ] has closed above bottom band by 31.4%. Bollinger Bands are 14.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.85 - 1.86 1.86 - 1.87
Low: 1.74 - 1.75 1.75 - 1.76
Close: 1.77 - 1.79 1.79 - 1.81
Company Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Headline News

Thu, 28 Mar 2024
Corvus Pharmaceuticals (NASDAQ:CRVS) Given Neutral Rating at Mizuho - Defense World

Wed, 27 Mar 2024
Mizuho Reiterates "Neutral" Rating for Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat

Thu, 21 Mar 2024
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript - Yahoo Finance

Wed, 20 Mar 2024
Corvus: Q4 Earnings Snapshot - Houston Chronicle

Tue, 19 Mar 2024
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript - Seeking Alpha

Tue, 19 Mar 2024
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results - Markets Insider

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 49 (M)
Shares Float 34 (M)
Held by Insiders 3.8 (%)
Held by Institutions 39.9 (%)
Shares Short 1,270 (K)
Shares Short P.Month 1,380 (K)
Stock Financials
EPS -0.57
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.79
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -25.7 %
Return on Equity (ttm) -57.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.48
Qtrly Earnings Growth 0 %
Operating Cash Flow -24 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -3.25
PEG Ratio 0
Price to Book value 2.29
Price to Sales 0
Price to Cash Flow -3.72
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android